BioArctic’s partner Eisai presents sales simulation for Leqembi® at its annual press conference
BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today published a presentation including a simulation[1]of potential future sales for Leqembi. According to Eisai's simulation, Leqembi sales will reach JPY 250 to 280 billion for their financial year (FY) 2027, which ends in March 2028. Eisai's presentation can be found on https://www.eisai.com/ir/library/presentations/index.html. This information is […]